- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Evommune Inc (EVMN)
The Evommune share price today is 20.71, view NYSE EVMN stock exchange data. Track the latest Evommune share price with real-time updates on EVMN stock performance including market cap, day range, 52-week range and dividend yield. Access EVMN charts, earnings dates and analyst estimates to support your investment decisions.
20.71
+0.22(+1.07%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.25
21.00
52 wk Range
13.89
33.20
EVMN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.2521.00
52 wk Range
13.8933.20
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EVMN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
52.25
Upside
+152.29%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings upwards for the upcoming period
- Form 144 Evommune For: 1 June
- Investing.com
- Evommune director Cohen sells $123,093 in stock
- Investing.com
- Evommune director Cohen sells $123,093 in stock
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 52.25
(+152.29% Upside)
Earnings
Latest Release
08-05-2026
EPS / Forecast
-0.64 / -0.76
Revenue / Forecast
-- / --
Compare EVMN to Peers and Sector
Metrics to compare | EVMN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEVMNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.8x | 5.9x | −0.5x | |
PEG Ratio | −0.11 | 0.55 | 0.00 | |
Price/Book | 2.4x | 1.6x | 2.6x | |
Price / LTM Sales | 74.1x | 6.5x | 3.0x | |
Upside (Analyst Target) | 153.8% | 281.7% | 58.6% | |
Fair Value Upside | Unlock | 3.7% | 10.2% | Unlock |
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Evommune (EVMN) Share Price Today?
The Evommune share price today is 20.71.
What is the current Evommune (EVMN) share price and day range?
As of 11-06-2026, the Evommune share price is 20.71, with a previous close of 20.49. The share price has ranged from 20.25 to 21.00 today, while the 52-week range spans from 13.89 to 33.20.
What Is the Evommune Market Cap?
As of today, Evommune market cap is 738.02M.
What Is the Evommune (EVMN) Share Price Target?
The average 12-month share price target for Evommune is 52.25, with a high estimate of 55 and a low estimate of 50. 10 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +152.29% Upside potential.
What Is Evommune's Earnings Per Share (TTM)?
The Evommune EPS (TTM) is -5.36.
When Is the Next Evommune Earnings Date?
Evommune will release its next earnings report on 02-09-2026.
From a Technical Analysis Perspective, Is EVMN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Evommune Trade On?
Evommune is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Evommune?
The stock symbol for Evommune is "EVMN."
How Many Times Has Evommune Stock Split?
Evommune has split 0 times.
How Many Employees Does Evommune Have?
Evommune has 48 employees.
What Is the EVMN Premarket Price?
EVMN's last pre-market stock price is 21.20. The pre-market share volume is 160.00, and the stock has changed by 0.71, or 3.47%.
What Is the EVMN After Hours Price?
EVMN's last after hours stock price is 21.17, the stock has changed by 0.68, or 3.32%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.